Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234519 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
A Phase 1 study, sponsored by AEterna Zentaris.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01234519: Clinical Trial Phase 1 study, sponsored by AEterna Zentaris.
NCT01234519 is a Phase 1 study that was terminated before completion, run by AEterna Zentaris. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01234519, a Phase 1 study, was terminated before completion, sponsored by AEterna Zentaris.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
Primary Outcome
Toxicity per Common Terminology Criteria for Adverse Events (CTCAE).
Interventions
- DRUG AEZS-108
- DRUG AEZS-108 at MTD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Why NCT01234519 stopped before completion
NCT01234519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which AEZS-108 is the first listed.
NCT01234519 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01234519 about?
NCT01234519 is a clinical study titled "A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy". The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
What is the current status of trial NCT01234519?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01234519?
The interventions under investigation include: AEZS-108 (DRUG), AEZS-108 at MTD (DRUG).
Who is sponsoring clinical trial NCT01234519?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01234519's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia